Last 12 months
Inside the activity.
0 purchase rows · 279 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 31 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 111 |
| Feb 2026 | 0 | 11 |
| Mar 2026 | 0 | 106 |
| Apr 2026 | 0 | 14 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 22, 2017 Filed Nov 24, 2017 23:55 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 25,263 | $129.97 | $3,283,432.11 |
DisclosureSEC source: 0001553878-17-000069 · primary_doc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,862 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 73,415 options exercised and sold by the reporting person were due to expire on December 12, 2017. F2 · price: Sale prices ranged from $129.39 to $130.35. Read SEC document |
| November 22, 2017 Filed Nov 24, 2017 23:55 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 73,415 | $31.39 | $2,304,496.85 |
DisclosureSEC source: 0001553878-17-000069 · primary_doc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 73,415 options exercised and sold by the reporting person were due to expire on December 12, 2017. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 74,000 | $0.00 Strike: $31.39 | $0.00 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · derivative · entry 9 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,415 Underlying: Common Stock · 74,000 shares Expires 2017-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F9 · derivative.exercise_date: The stock option vested as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. F1 · derivative.expiration_date: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 600 | $130.22 | $78,130.80 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 7 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,710 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F7 · price: Sale prices ranged from $130.15 to $130.41. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 4,850 | $129.57 | $628,414.50 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 6 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,310 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F6 · price: Sale prices ranged from $129.11 to $130.00. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 10,571 | $128.48 | $1,358,204.36 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 5 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,160 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F5 · price: Sale prices ranged from $128.09 to $129.08. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 7,120 | $127.54 | $908,084.80 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,731 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F4 · price: Sale prices ranged from $127.08 to $128.06. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 28,399 | $126.60 | $3,595,398.60 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,851 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F3 · price: Sale prices ranged from $126.08 to $127.05. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 22,460 | $125.54 | $2,819,718.24 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,250 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F2 · price: Sale prices ranged from $125.07 to $126.05. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 74,000 | $31.39 | $2,322,860.00 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 22:25 UTC |
Mason MichaelVP, Finance and Treasurer
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 1,800 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001553878-17-000066 · edgardoc.xml · derivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective November 6, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 22:26 UTC |
Vaishnaw AkshayEVP, R&D
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 7,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001553878-17-000067 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective November 6, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 22:25 UTC |
KEATING LAURIESVP, GC & Secretary
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 3,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001553878-17-000064 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective November 6, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 22:25 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 16,250 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001553878-17-000065 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 16,250 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective November 6, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 22:25 UTC |
Greene Barry EPresident
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 10,000 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001553878-17-000063 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective November 6, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| November 02, 2017 Filed Nov 4, 2017 00:14 UTC |
Ausiello Dennis ADirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $30.09 | $0.00 |
DisclosureSEC source: 0001553878-17-000057 · edgardoc.xml · derivative · entry 4 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2017. F3 · derivative.exercise_date: The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant. Read SEC document |
| November 02, 2017 Filed Nov 4, 2017 00:14 UTC |
Ausiello Dennis ADirector
|
SaleCommon Stock | 20,000 | $130.00 | $2,600,000.00 |
DisclosureSEC source: 0001553878-17-000057 · edgardoc.xml · nonDerivative · entry 2 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2017. Read SEC document |
| November 02, 2017 Filed Nov 4, 2017 00:14 UTC |
Ausiello Dennis ADirector
|
Exercise / conversionCommon Stock | 20,000 | $30.09 | $601,800.00 |
DisclosureSEC source: 0001553878-17-000057 · edgardoc.xml · nonDerivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2017. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 21:33 UTC |
Vaishnaw AkshayEVP, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 33,666 | $0.00 Strike: $21.35 | $0.00 |
DisclosureSEC source: 0001553878-17-000055 · primary_doc.xml · derivative · entry 7 Vaishnaw Akshay · CIK 0001458494 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,666 shares Expires 2018-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2017. F7 · derivative.exercise_date: The stock option vested as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 21:33 UTC |
Vaishnaw AkshayEVP, R&D
|
SaleCommon Stock | 3,693 | $122.79 | $453,463.47 |
DisclosureSEC source: 0001553878-17-000055 · primary_doc.xml · nonDerivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,535 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2017. F5 · price: Sale prices ranged from $122.45 to $123.01. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 21:33 UTC |
Vaishnaw AkshayEVP, R&D
|
SaleCommon Stock | 17,755 | $121.69 | $2,160,605.95 |
DisclosureSEC source: 0001553878-17-000055 · primary_doc.xml · nonDerivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,228 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2017. F4 · price: Sale prices ranged from $121.26 to $122.19. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 21:33 UTC |
Vaishnaw AkshayEVP, R&D
|
SaleCommon Stock | 11,418 | $120.78 | $1,379,066.04 |
DisclosureSEC source: 0001553878-17-000055 · primary_doc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,983 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2017. F3 · price: Sale prices ranged from $120.32 to $121.25. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 21:33 UTC |
Vaishnaw AkshayEVP, R&D
|
SaleCommon Stock | 800 | $119.79 | $95,832.00 |
DisclosureSEC source: 0001553878-17-000055 · primary_doc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,401 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2017. F2 · price: Sale prices ranged from $119.30 to $120.28. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 21:33 UTC |
Vaishnaw AkshayEVP, R&D
|
Exercise / conversionCommon Stock | 33,666 | $21.35 | $718,769.10 |
DisclosureSEC source: 0001553878-17-000055 · primary_doc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2017. Read SEC document |
| October 16, 2017 Filed Aug 14, 2018 21:54 UTC |
Soni Manmeet SinghChief Financial Officer
|
OtherCommon Stock | 11 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000048 · edgardoc.xml · nonDerivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 13 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 23:45 UTC |
Greene Barry EPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 85,316 | $0.00 Strike: $21.35 | $0.00 |
DisclosureSEC source: 0001553878-17-000054 · primary_doc.xml · derivative · entry 4 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,316 shares Expires 2018-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 23:45 UTC |
Greene Barry EPresident
|
SaleCommon Stock | 85,316 | $125.00 | $10,664,500.00 |
DisclosureSEC source: 0001553878-17-000054 · primary_doc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,428 F1 · kind: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 23:45 UTC |
Greene Barry EPresident
|
Exercise / conversionCommon Stock | 85,316 | $21.35 | $1,821,496.60 |
DisclosureSEC source: 0001553878-17-000054 · primary_doc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. Read SEC document |
| September 22, 2017 Filed Feb 9, 2018 22:04 UTC |
Mason MichaelVP, Finance and Treasurer
|
OtherCommon Stock | 1,950 | $115.47 | $225,166.50 |
DisclosureSEC source: 0001553878-18-000001 · primary_doc.xml · nonDerivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · By Managed Account Disclosed balance after: 226 F1 · ownership.nature: The reporting person has diversified his retirement plan by selling shares of ALNY common stock in his 401(k) plan received from the ALNY 401(k) matching contribution program. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 21:05 UTC |
Greene Barry EPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,359 | $0.00 Strike: $18.66 | $0.00 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · derivative · entry 8 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,641 Underlying: Common Stock · 5,359 shares Expires 2022-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 21:05 UTC |
Greene Barry EPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,485 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · derivative · entry 7 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,915 Underlying: Common Stock · 6,485 shares Expires 2021-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 21:05 UTC |
Greene Barry EPresident
|
Exercise / conversionCommon Stock | 5,359 | $18.66 | $99,998.94 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · nonDerivative · entry 4 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 21:05 UTC |
Greene Barry EPresident
|
Exercise / conversionCommon Stock | 6,485 | $7.10 | $46,043.50 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · nonDerivative · entry 3 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 21:11 UTC |
Vaishnaw AkshayEVP, R&D
|
GrantPerformance Stock Option 2013 (right to buy) · Derivative | 10,834 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001553878-17-000053 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,834 Underlying: Common Stock · 10,834 shares Expires 2023-12-17 F1 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective September 20, 2017, the compensation committee of the company determined the second performance criteria had been met and the option will vest as to one-third of the shares. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 21:09 UTC |
Mason MichaelVP, Finance and Treasurer
|
GrantPerformance Stock Option 2013 (right to buy) · Derivative | 1,667 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001553878-17-000052 · edgardoc.xml · derivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Common Stock · 1,667 shares Expires 2023-12-17 F1 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective September 20, 2017, the compensation committee of the company determined the second performance criteria had been met and the option will vest as to one-third of the shares. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 21:08 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
GrantPerformance Stock Option 2013 (right to buy) · Derivative | 25,000 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001553878-17-000051 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2023-12-17 F1 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective September 20, 2017, the compensation committee of the company determined the second performance criteria had been met and the option will vest as to one-third of the shares. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 21:05 UTC |
Greene Barry EPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 76,815 | $0.00 Strike: $31.39 | $0.00 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · derivative · entry 9 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,815 shares Expires 2017-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. The 76,815 options exercised and sold by the reporting person were due to expire on December 12, 2017. F4 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. F1 · derivative.expiration_date: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. The 76,815 options exercised and sold by the reporting person were due to expire on December 12, 2017. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 21:05 UTC |
Greene Barry EPresident
|
GrantPerformance Stock Option 2013 (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · derivative · entry 6 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2023-12-17 F3 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by the compensation committee of the Company. Effective September 20, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option was vested as to one-third of the shares. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 21:05 UTC |
Greene Barry EPresident
|
SaleCommon Stock | 76,815 | $100.00 | $7,681,500.00 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,584 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. The 76,815 options exercised and sold by the reporting person were due to expire on December 12, 2017. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 21:05 UTC |
Greene Barry EPresident
|
Exercise / conversionCommon Stock | 76,815 | $31.39 | $2,411,222.85 |
DisclosureSEC source: 0001553878-17-000047 · primary_doc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. The 76,815 options exercised and sold by the reporting person were due to expire on December 12, 2017. Read SEC document |
| July 25, 2017 Filed Aug 14, 2018 21:54 UTC |
Soni Manmeet SinghChief Financial Officer
|
OtherCommon Stock | 2 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000048 · edgardoc.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 2 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:35 UTC |
Vaishnaw AkshayEVP, R&D
|
GrantPerformance Stock Option 2014 (right to buy) · Derivative | 11,709 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001553878-17-000046 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,418 Underlying: Common Stock · 11,709 shares Expires 2024-12-17 F1 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective July 7, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option vested as to one-third of the shares. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:35 UTC |
Mason MichaelVP, Finance and Treasurer
|
GrantPerformance Stock Option 2014 (right to buy) · Derivative | 2,750 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001553878-17-000045 · edgardoc.xml · derivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 2,750 shares Expires 2024-12-17 F1 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective July 7, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option vested as to one-third of the shares. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:34 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
GrantPerformance Stock Option 2014 (right to buy) · Derivative | 25,000 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001553878-17-000044 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires 2024-12-17 F1 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective July 7, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option vested as to one-third of the shares. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:34 UTC |
KEATING LAURIESVP, GC & Secretary
|
GrantPerformance Stock Option 2014 (right to buy) · Derivative | 1,987 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001553878-17-000043 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,974 Underlying: Common Stock · 1,987 shares Expires 2024-12-17 F1 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective July 7, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option vested as to one-third of the shares. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:34 UTC |
Greene Barry EPresident
|
GrantPerformance Stock Option 2014 (right to buy) · Derivative | 15,875 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001553878-17-000042 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,750 Underlying: Common Stock · 15,875 shares Expires 2024-12-17 F1 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective July 7, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option vested as to one-third of the shares. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 21:45 UTC |
Vaishnaw AkshayEVP, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 328 | $0.00 Strike: $21.35 | $0.00 |
DisclosureSEC source: 0001553878-17-000036 · primary_doc.xml · derivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,666 Underlying: Common Stock · 328 shares Expires 2018-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 21:45 UTC |
Vaishnaw AkshayEVP, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,340 | $0.00 Strike: $18.66 | $0.00 |
DisclosureSEC source: 0001553878-17-000036 · primary_doc.xml · derivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,641 Underlying: Common Stock · 1,340 shares Expires 2022-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 21:45 UTC |
Vaishnaw AkshayEVP, R&D
|
Tax withholdingCommon Stock | 430 | $74.31 | $31,953.30 |
DisclosureSEC source: 0001553878-17-000036 · primary_doc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,535 Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 21:45 UTC |
Vaishnaw AkshayEVP, R&D
|
Exercise / conversionCommon Stock | 1,340 | $18.66 | $25,004.40 |
DisclosureSEC source: 0001553878-17-000036 · primary_doc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.